These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31929543)

  • 1. Polymer-free sirolimus-eluting stent use in Europe and Asia: Ethnic differences in demographics and clinical outcomes.
    Krackhardt F; Waliszewski M; Wan Ahmad WA; Kočka V; Toušek P; Janek B; Trenčan M; Krajči P; Lozano F; Garcia-San Roman K; Otaegui Irurueta I; Garcia Del Blanco B; Wachowiak L; Vilalta Del Olmo V; Fernandez Nofrerías E; Ho Jeong M; Jung BC; Han KR; Piot C; Sebagh L; Rischner J; Pansieri M; Leschke M; Ahn TH
    PLoS One; 2020; 15(1):e0226606. PubMed ID: 31929543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity score matched all comers population treated with ultra-thin strut bare metal and sirolimus-probucol coated drug-eluting stents of identical stent architecture.
    Krackhardt F; Rosli MA; Leschke M; Schneider A; Sperling C; Heang TM; Pons M; Sousa PJ; Kherad B; Waliszewski M
    Catheter Cardiovasc Interv; 2018 Jun; 91(7):1221-1228. PubMed ID: 28944613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice.
    Krackhardt F; Kočka V; Waliszewski M; Toušek P; Janek B; Trenčan M; Krajči P; Lozano F; Roman KG; Otaegui I; Del Blanco BG; Del Olmo VV; Nofrerías EF; Wachowiak L; Heang TM; Ahn TH; Jeong MH; Jung BC; Han KR; Piot C; Sebagh L; Rischner J; Pansieri M; Leschke M
    Medicine (Baltimore); 2020 Feb; 99(8):e19119. PubMed ID: 32080086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6‑month vs. 12‑month dual-antiplatelet therapy (DAPT).
    Krackhardt F; Waliszewski M; Rischner J; Piot C; Pansieri M; Ruiz-Poveda FL; Boxberger M; Noutsias M; Ríos XF; Kherad B
    Herz; 2019 Aug; 44(5):433-439. PubMed ID: 29356832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
    Rozemeijer R; Stein M; Voskuil M; van den Bor R; Frambach P; Pereira B; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Agostoni P; Roes KC; Doevendans PA; Stella PR;
    Circulation; 2019 Jan; 139(1):67-77. PubMed ID: 30586704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
    Wykrzykowska J; Serruys P; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; Di Mario C; Van Geuns RJ; Van Es GA; Juni P; Windecker S
    EuroIntervention; 2011 Nov; 7(7):789-95. PubMed ID: 22027687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Clinical Outcomes Following Single versus Multivessel Percutaneous Coronary Intervention Using Biodegradable Polymer Coated Sirolimus-Eluting Stent in an All-comers Patient Population.
    Chandwani P; Verma P; Saxena S; Ramachandran PK; Abhyankar A; Sandhu MS; Parikh N; Bhupali A; Jain S; Prajapati J
    Cardiovasc Hematol Agents Med Chem; 2016; 14(1):39-48. PubMed ID: 26585397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year outcomes of a BioMime™ Sirolimus-Eluting Coronary Stent System with a biodegradable polymer in all-comers coronary artery disease patients: The meriT-3 study.
    Jain RK; Chakravarthi P; Shetty R; Ramchandra P; Polavarapu RS; Wander GS; Mohan B; Banker DN; Dharmadhikari A; Bansal SS; Jain N; Solanki D; Dhakaan J; Sharma VP; Mohanan PP; Ashokan PK; Manjunath BV; Hiregoudar N; Patil C; Balakrishnan N
    Indian Heart J; 2016; 68(5):599-603. PubMed ID: 27773396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
    Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial.
    Silber S; Windecker S; Vranckx P; Serruys PW;
    Lancet; 2011 Apr; 377(9773):1241-7. PubMed ID: 21459430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization.
    Yamaji K; Zanchin T; Zanchin C; Stortecky S; Koskinas KC; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Valgimigli M; Billinger M; Pilgrim T; Heg D; Windecker S; Räber L
    Circ Cardiovasc Interv; 2018 Sep; 11(9):e006741. PubMed ID: 30354590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
    Pilgrim T; Heg D; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Fahrni T; Moschovitis A; Noble S; Eberli FR; Wenaweser P; Jüni P; Windecker S
    Lancet; 2014 Dec; 384(9960):2111-22. PubMed ID: 25189359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seven-year clinical outcomes in patients undergoing percutaneous coronary intervention with biodegradable polymer coated sirolimus-eluting stent: Results from a single-center real-world experience.
    Abhyankar A; Kaul U; Sinha SK
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S280-S284. PubMed ID: 30595275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Kandzari DE; Mauri L; Koolen JJ; Massaro JM; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    Lancet; 2017 Oct; 390(10105):1843-1852. PubMed ID: 28851504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the LEADERS all-comers randomized trial.
    Grundeken MJ; Wykrzykowska JJ; Ishibashi Y; Garg S; de Vries T; Garcia-Garcia HM; Onuma Y; de Winter RJ; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; di Mario C; Meier B; Jüni P; Yazdani A; Copt S; Windecker S; Serruys PW
    Catheter Cardiovasc Interv; 2016 Jun; 87(7):E248-60. PubMed ID: 26649651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents.
    Kandzari DE; Koolen JJ; Doros G; Massaro JJ; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    J Am Coll Cardiol; 2018 Dec; 72(25):3287-3297. PubMed ID: 30257191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial.
    Wöhrle J; Markovic S; Rottbauer W; Muramatsu T; Kadota K; Vázquez-González N; Odenstedt J; Serra A; Antoniucci D; Varenne O; Saito S; Wijns W
    EuroIntervention; 2016 Jun; 12(2):e167-74. PubMed ID: 27290676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients.
    Sinha N; Rai H; Cassese S; Kumar S; Kapoor A; Kastrati A
    Coron Artery Dis; 2016 Aug; 27(5):385-90. PubMed ID: 27124380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.